U.S. Markets close in 2 hrs 55 mins

AIM ImmunoTech Inc. (AIM)

NYSE American - Nasdaq Real Time Price. Currency in USD
Add to watchlist
1.7350+0.0550 (+3.27%)
As of 1:05PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.6800
Open1.7400
Bid1.7300 x 1300
Ask1.7400 x 1000
Day's Range1.7000 - 1.7500
52 Week Range0.3900 - 7.1100
Volume1,006,936
Avg. Volume2,321,246
Market Cap70.591M
Beta (5Y Monthly)-0.84
PE Ratio (TTM)N/A
EPS (TTM)-5.8730
Earnings DateNov 13, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.25
  • AIM Announces Milestone in COVID-19 Treatment and Prevention Efforts with First Patient Dosed in Study Evaluating Ampligen as Part of Combination Treatment for Patients with Cancer and COVID-19
    GlobeNewswire

    AIM Announces Milestone in COVID-19 Treatment and Prevention Efforts with First Patient Dosed in Study Evaluating Ampligen as Part of Combination Treatment for Patients with Cancer and COVID-19

    OCALA, Fla., Nov. 25, 2020 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced developments in its work to develop new treatments or preventive strategies for COVID-19, the disease caused by SARS-CoV-2. First, AIM reports that Roswell Park Comprehensive Cancer Center’s Phase 1/2a study evaluating the two-drug combination of AIM’s Ampligen and interferon alpha-2b as a potential early-onset treatment for patients with cancer and mild-to-moderate COVID-19 is fully underway, with the first patient enrolled and treated on the study.AIM is a collaborator on that clinical trial, which is funded in part through grants from the National Cancer Institute and AIM, as well as institutional support from Roswell Park. AIM is providing Ampligen at no charge for this study. Full details about this trial, which is led by Roswell Park co-Principal Investigators, Drs. Brahm Segal and Pawel Kalinski, are available at ClinicalTrials.gov.Additionally, the AIM team is working to develop: * An intranasal prophylaxis strategy for frontline workers, the elderly and other high-risk patients, including those with co-morbidities such as cancer; and * An effective therapy for COVID-19 Long Haulers, so named due to the persistence of their symptoms after their infections have ended. According to AIM CEO Thomas K. Equels: “While major global pharmaceutical companies have largely focused their efforts on the critical need for a COVID-19 vaccine – with Moderna and Pfizer recently announcing significant and hopeful results – AIM believes there is an equally critical health need to develop an early-onset treatment for people already infected with the disease. We greatly appreciate the leadership of Dr. Brahm Segal and Dr. Pawel Kalinski, as well as the tremendous efforts of the entire team at Roswell Park. We look forward to providing further updates as this critical trial progresses.”About AIM ImmunoTech Inc.AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus.Cautionary StatementThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate” and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Among other things, for those statements, the Company claims the protection of safe harbor for forward-looking statements contained in the PSLRA. Any forward-looking statements set forth in this press release speak only as of the date of this press release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. For instance, no assurance can be given as to whether the above mentioned study will prove successful. No assurance can be given as to whether current or planned immuno-oncology clinical trials will be successful or yield favorable data and the trials are subject to many factors including lack of regulatory approval(s), lack of study drug, or a change in priorities at the institutions sponsoring other trials. In addition, initiation of planned clinical trials may not occur secondary to many factors including lack of regulatory approval(s) or lack of study drug. Even if such clinical trials are initiated, the Company cannot assure that the clinical studies will be successful or yield any useful data or require additional funding. Some of the world’s largest pharmaceutical companies and medical institutions are racing to find a treatment for COVID-19. Even if Ampligen proves effective in combating the virus, no assurance can be given that the Company’s actions toward proving this will be given first priority or that another treatment that eventually proves capable will not make its efforts ultimately unproductive. Operating in foreign countries carries with it a number of risks, including potential difficulties in enforcing intellectual property rights. The Company cannot assure that its potential foreign operations will not be adversely affected by these risks.Contacts: Crescendo Communications, LLC Phone: 212-671-1021 Email: aim@crescendo-ir.com AIM ImmunoTech Inc Phone: 800-778-4042 Email: IR@aimimmuno.com

  • AIM ImmunoTech Inc. (NYSEMKT:AIM) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
    Simply Wall St.

    AIM ImmunoTech Inc. (NYSEMKT:AIM) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

    AIM ImmunoTech Inc. (NYSEMKT:AIM) last week reported its latest third-quarter results, which makes it a good time for...

  • What Can We Learn About AIM ImmunoTech's (NYSEMKT:AIM) CEO Compensation?
    Simply Wall St.

    What Can We Learn About AIM ImmunoTech's (NYSEMKT:AIM) CEO Compensation?

    This article will reflect on the compensation paid to Thomas Equels who has served as CEO of AIM ImmunoTech Inc...